|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||64.48 - 64.91|
|52 Week Range||53.55 - 66.40|
|PE Ratio (TTM)||-5.41|
|Expense Ratio (net)||0.56%|
Merck’s (MRK) diabetes portfolio includes drugs used for controlling the blood sugar levels for patients with diabetes.
In August 2017, JAZZ's Vyxeos liposome injection for the treatment of adult individuals with rapidly progressing or life t-AML received FDA approval.
On July 31, 2017, Eli Lilly and Boehringer Ingelheim announced that the companies would support one of the new programs by the American College of Cardiology.